FDA Blocks China Pharma Site After Critical GMP Failures Trigger Import Alert
FDA targets Foshan Miwei after major GMP violations in OTC manufacturing. The company fails to test active ingredients and skips microbiological controls. In addition, it lacks a validated stability program.
Quality unit oversight also fails to control deviations and change processes. Consequently, FDA places the site under import alert, blocking US entry. This action reflects increased regulatory pressure on imported pharmaceutical and OTC products entering the US market in 2026. It also signals stricter enforcement on manufacturing controls in high-risk production environments, especially where batch release and testing systems remain weak or incomplete.
FDA Shuts Down US OTC Manufacturer After Major Validation Control Failures
FDA issues a warning letter to Lexia LLC after discovering major GMP gaps. The company limits testing to basic physical checks and ignores full release requirements.
It also relies on supplier certificates without validation. Moreover, no stability program or process validation exists, raising serious consistency risks.
FDA concludes the site lacks a functioning quality unit and halts production. This case highlights growing FDA focus on fundamental GMP infrastructure failures, particularly in small-scale OTC manufacturing sites. It also reinforces expectations for validated processes, robust supplier qualification, and documented stability programs across all marketed products.
FDA Challenges Incyte Over Misleading Drug Efficacy Claims
FDA’s OPDP issues an untitled letter to Incyte over Niktimvo promotion. The company overstates response rates and misrepresents clinical results.
However, FDA data confirms only partial responses, not full remission. Therefore, the agency calls the messaging misleading.
Visual claims suggesting organ-specific benefits also conflict with clinical trial evidence. This action reflects tighter FDA scrutiny on digital pharmaceutical promotion, especially where clinical data interpretation may influence physician and patient perception of treatment efficacy and real-world outcomes.
FDA Intensifies Global Pharma Oversight Over Rising Data Integrity Risks
FDA enforcement in 2026 shows a clear global pattern. Manufacturing failures, data integrity gaps, and misleading claims now trigger faster regulatory action.
Inspection focus intensifies on OOS investigations, audit trails, and validation systems. As a result, pharma companies face higher pressure across both GMP operations and digital compliance. This trend reinforces a broader shift toward integrated inspection models, where manufacturing quality, electronic system integrity, and promotional accuracy are assessed under a unified regulatory risk framework.
This case reflects the kind of real-world regulatory risks that modern pharma quality systems are increasingly expected to control.
Curious how pharma companies systematically prevent FDA-level GMP and data integrity failures in real-world operations? Explore selected regulatory and compliance case studies here: Client Cases
Source: raps